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Abstract
Background: The impact of vitamin D3 (VD3) on obesity has been reported in the past. Our study was aimed at
investigating the possible mechanisms by which VD3 affects obesity induced by a high fat diet.
Methods: Eight-week-old C57BL/6 J male mice were fed a normal- or high-fat diet for 9 weeks and were treated
with a gavage of vehicle (corn oil) or cholecalciferol (50 μg/kg, daily). Body weight, white adipose tissue weight,
blood lipid and glucose levels were measured. In addition, we investigated the expression of 1,25(OH)2D3
(calcitriol)/VDR-regulated genes involved in energy and lipid metabolism, such as of uncoupling protein 3 (UCP3),
by using qRT-PCR in the liver, adipose tissue, skeletal muscle and C2C12, L6, and H-EMC-SS cells. We also measured
UCP3 promoter transcription in the same cell lines using a Dual Luciferase Assay. Furthermore, we analyzed the
binding site consensus sequences of VDR on the UCP3 promoter.
Results: Mice consuming a high-fat diet treated with cholecalciferol had lower body weight and adipose tissue
weight and higher expression of UCP3 compared to the other treatment groups. Changes in the expression of
genes correlated with calcitriol/VDR. Luciferase activity was dose-dependently associated with calcitriol/VDR levels.
We confirmed the functional VDR binding site consensus sequences at -2200, -1561, -634, and +314 bp in the UCP3
promoter region.
Conclusion: We suggest that VD3/VDR inhibits weight gain by activating UCP3 in the muscles.
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Background
Obesity is associated with vitamin D deficiency, and both
are areas of active public health concern. Vitamin D
(1,25(OH)2D3) is a steroid hormone that has a range of
physiological functions in skeletal and nonskeletal tis-
sues, and can contribute to prevent and/or treat several
diseases. We hypothesize that increased UCP3 expres-
sion promotes mitochondria activity and fatty acid oxi-
dation. We provide evidence that VD3/VDR regulates
body weight and white adipose tissues weight without
changing food intake and blood lipid levels. We confirmed
UCP3 gene transcription is initiated by 1,25(OH)2D3
(calcitriol)/VDR binding to the UCP3 promoter on the
molecular basis, which reinforces energy metabolism,
resulting in resistance to obesity caused by a high fat diet,
as dealt with in this paper.
Introduction
Obesity, most commonly caused by excessive dietary cal-
ories due to a high-fat diet, is increasing in prevalence
worldwide [1]. Obesity is associated with several chronic
diseases, including fatty liver, heart disease, type 2 dia-
betes mellitus, certain types of cancer, and osteoarthritis
[2, 3]. The balance between energy intake and energy
utilization maintains body weight. Energy is obtained by
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consuming calories and can be stored in adipose tissues or
can be utilized by the body to sustain basic cellular func-
tions and physical activities [4]. Since energy homeostasis
is maintained by signals from feedback loops that regulate
food intake, energy expenditure, lipid metabolism, and
glucose metabolism [5], variation in the genes involved in
these pathways likely influences the development of
obesity.
Uncoupling proteins (UCPs) belong to the family of
mitochondrial transporter proteins that are important in
energy homeostasis. UCPs have become prominent in the
fields of thermogenesis, obesity, diabetes, and free-radical
biology and have been considered candidate genes for
obesity and insulin resistance [6]. Among the five subtypes
of UCPs, UCP3 is a member of the mitochondrial
transporter super family and is expressed predominantly
in skeletal muscles [7, 8]. UCP3 mediates energy expend-
iture via mitochondrial proton leak and lipid metabolism
[9–12] and is involved in fatty acid translocation [13]. Re-
duction in the function or expression of UCP3 likely de-
creases energy expenditure or increases fat storage of
energy [14]. UCP3 is negatively correlated with body mass
index (BMI) [15], suggesting a potential link between
UCP3 and obesity, potentially by the proposed roles of
UCP3 in facilitating fatty acid oxidation [16] and prevent-
ing triglyceride accumulation [17]. Therefore, UCP3 likely
modulates body weight, but further investigation is needed
to confirm this.
Vitamin D (VD) is a fat-soluble vitamin that is either
synthesized in the skin after exposure to solar UVB radi-
ation or obtained from the diet. VD regulates both bone
metabolism and calcium-phosphorus homeostasis [18].
In humans, vitamin D3 (VD3, cholecalciferol) is trans-
formed to 1, 25-dihydroxyvitamin D3 (1,25(OH)2D3)
(calcitriol), the most active form [19]. Calcitriol func-
tions are primarily activated by its nuclear receptor, vita-
min D receptor (VDR), which recruits its preferred
dimerization partner, retinoid X receptor (RXR), to form
a heterodimer. This complex acts as a ligand-dependent
transcription factor that combines with vitamin D re-
sponse elements (VDRE) in the promoter regions of tar-
get genes [20, 21].
Recent epidemiological investigations found that low
serum calcitriol levels are associated with a higher BMI
and greater body fat [22, 23]. Additionally, elevated dietary
VD intake and serum 25(OH)D levels are associated with
reduced omental adipocyte size and lower visceral adipos-
ity, which have important clinical implications [24]. In-
creasing evidence suggests that VD3 supplementation
limits weight gain induced by high-fat diets due to
increased lipid oxidation [25]. Administration of calcitriol
regulates peroxisome proliferator-activated receptor α
(PPARα), which prevents high-fat diets-induced body
weight gain by inhibiting lipogenesis [26]. Reports
regarding VD3 and obesity have been contradictory; for
example, VDR knock-out mice are resistant to high-fat
diets-induced weight gain [27] and show a slower growth
rate and accumulate less fat mass [28]. Therefore, further
research on the effect of VD3/VDR on obesity is needed.
To investigate the influence of VD3/VDR on body weight
and lipid, we investigated the energy metabolism in obese
mice consuming a high-fat diet and a possible consensus
sequences in the UCP3 promoter for VDR.
Methods
Animal and treatment
Eight-week-old male C57BL/6 J mice (Japan SLC, Shizuoka,
Japan) were acclimated in the animal facility under a 12-h
light/dark cycle prior to the experiment. For 9 weeks, the
mice were fed a control normal-fat diet (group NFD:
10 kcal% fat (lard)), (D12450B, Research Diets Inc, NJ, US)
or a high-fat diet (groups HFD and HFVD: 45 kcal% fat
(lard)), (D12451, Research Diets Inc). We used HFD feeding
as previously described [25]. Both NFD and HFD mice
were treated with vehicle (1 % ethanol, 9 % pure water,
90 % corn oil). HFVD mice were treated with 50 μg/kg
body wt/d cholecalciferol (VD3) (C0314, TCI, Tokyo Japan)
administered by gavage daily. We determined the dose of
VD3 to feed as previously described [18]. Body weight was
measured every day and food intake was calculated per
cage. Mice were fasted 24 h before sacrificing, at which
point perfused normal saline from the left ventricle of the
heart, blood, liver, mesenteric adipose, kidney adipose,
epididymis adipose, and thigh rectus femoris muscle were
collected and analyzed.
Blood serum analysis
Mouse blood samples were placed on ice for 1 h and then
centrifuged at 3500 × g for 90 s. The blood serum was col-
lected and total cholesterol (T-CHO), low density
lipoprotein-cholesterol (LDL-C), high density lipoprotein-
cholesterol (HDL-C), and triglyceride (TG) were measured
using LabAssay™ Cholesterol (294-65801, Wako Pure
Chemical Industries, Ltd, Japan), LabAssay™ Glucose (298-
65701), LabAssay™ Triglyceride (290-63701), according to
manufacturer’s instructions.
Tissue sample RNA extraction for quantitative real-time
PCR and PCR agarose electrophoresis
Total RNA was extracted from homogenized ~1 mm
sliced tissue samples using the RiboZol RNA extraction
reagents (N580, AMRESCO, US). cDNA was synthesized
using iScript Reverse Transcription Supermix (170-8841,
BIO-RAD, US) and the following conditions: 25 °C for
5 min, 42 °C for 30 min, 85 °C for 5 min, 4 °C until use.
Real-time qPCR was conducted using SsoAdvanced
Universal SYBR Green Supermix (172-5271,BIO-RAD).
The cycle conditions were as follows: 95 °C for 1 min
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followed by 39 cycles of 95 °C for 5 s and 59.5 °C for
10 s. The level of UCP3 mRNA was evaluated from
thigh rectus femoralis muscle samples and the house-
keeping gene GAPDH was used as an internal control.
Expression of liver X receptors (LXRs), farnesoid X re-
ceptor (FXR), peroxisome proliferator-activated receptor
(PPAR), and related genes were measured in the same
methods.
To amplify VDR and β-actin, PCR was performed as
follows: 30 cycles of 98 °C 10 s, 55 °C 30 s, and 72 °C
15 s. VDR and β-actin PCR products (188 bp and
192 bp, respectively) were confirmed by 2 % agarose gel
electrophoresis, ethidium bromide staining, and UV light
visualization. The primers used are listed in Additional
file 1: Table S1.
Cell culture
Mouse C2C12 muscle cells (C2C12), rat L6 muscle cells
(L6), H-EMC-SS chondrosarcoma cells, and human em-
bryonic kidney cells (HEK293) were purchased from JCRB
Cell Bank (National Institute of Biomedical Innovation,
Tokyo, Japan). Cells were maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM) (05919, Nissui Pharmaceut-
ical, Japan) containing 10 % FBS (SH30910.03, Thermo
Scientific, US), 1 % penicillin (168-23191, Wako) and
1 % L(+) - Glutamine (074-00522, Wako) at 37 °C in 5 %
CO2. Cultures were passaged in a subcultivation ratio of
1:3 - 1:4 every two days using 0.25 % w/v Trypsin-
1 mmol/L EDTA-4Na Solution (201-16945, Wako).
Plasmid construction
The human UCP3 promoter was generously gifted by
Dr. Jean A. Boutin (Biotechnologie, Pharmacologie
Moléculaire et Cellulaire, Institut de Recherches SER-
VIER, France). The UCP3 promoter was digested with
XbaI and NcoI and inserted into the pGL4.10-basic vec-
tor (Promega Corp., WI) containing the luciferase gene
(luc), resulting in a luciferase eukaryotic expression plas-
mid, which we named UCP3-pro-Luc. The plasmid for
mouse UCP3 mRNA interference was generously gifted
by Prof. Wolfgang F. Graier (Institute of Molecular Biol-
ogy & Biochemistry, Center of Molecular Medicine
Medical University of Graz, Austria).
Cell transfection, calcitriol stimulation, and quantitative
real-time PCR (qRT-PCR)
We measured mRNA expression in C2C12, L6, and H-
EMC-SS untransfected cells or cells transfected with
pCMX-VDR, expression plasmid of VDR (pCMX-VDR
was provided by K. Umesono and R. M. Evans (Salk In-
stitute, San Diego, CA)). One dish (100 mm) of 5–6 X
105 cells were seeded in a 6-well plate and changed to
Opti-MEM (31985-070, Gibco, US) until the cells were
70–80 % confluent. pCMX-VDR (100 ng/well) was
transfected using Lipofectamine 2000 DNA transfection
reagent (11668-019, Invitrogen, Life Technologies, US)
for 5 h then the medium was changed to DMEM. Calci-
triol (50 nM) was added and cells were incubated for
24 h. For mRNA analysis, total RNA was isolated using
the RiboZol RNA extraction reagents. cDNA synthesis
and real time PCR were conducted as described above.
UCP3 mRNA expression was measured in C2C12, L6,
and H-EMC-SS cells. The housekeeping gene GAPDH
was used as an internal control.
Calcium phosphate cell transfection, calcitriol stimulation,
and dual luciferase assay
The reporter plasmid (UCP3-pro-luc, 100 ng/mL), expres-
sion plasmid of VDR (pCMX-VDR, 50 ng/mL), and in-
ternal control plasmid (pGL 4.70 10 ng/mL) were
transfected into HEK 293, C2C12, and H-EMC-SS cells
using 0.01 M Tris-HCl, 2.5 M CaCl2, and 2 ×HBS. About
5 h after transfection, the media was changed to DMEM.
A gradient of calcitriol (0.1–100 nM) was added and the
cells were stimulated for 24 h. The cells were harvested
using 1× Passive Lysis Buffer (E194A, Promega, WI) and
measured by the Dual Luciferase Reporter Assay System
(E1960, Promega, Corp. WI) according to the manufac-
turer’s instructions.
Candidate VDRE sequence search using the UCP3
promoter deletion model
PSORTII (PSORTII computer software provided by the
Human Genome Center, Institute for Medical Science,
Tokyo University, Japan) was used to detect putative
VDREs. All settings used were default settings. Of the
detected sequences, those with significant similarities or
identical to the mouse osteopontin were selected [29].
Then we generated five deletion constructs containing
the candidate VDREs to screen for functional regions
(Fig. 5a). Next we subcloned ten putative VDREs from
the 5’-flanking region of UCP3 and prepared ten re-
porter constructs, each containing a VRDE candidate as
previously prescribed [30]. In briefly, the reporter plas-
mid VDRE-tk-luc contains one copy of the mouse osteo-
pontin VDRE upstream of a 151 bp truncated thymidine
kinase promoter, inserted between the SacI and HindIII
sites of the pGL 4.10-basic vector and was used as the
positive control. Each candidate was inserted into
VDRE-tk-luc substituting for the mouse osteopotin
VDRE. The candidates consisted of -2200: designates as
①, -2043: ②, -1867: ③, -1561: ④, -634: ⑤, -595: ⑥, -80:
⑦, -1: ⑧, +162: ⑨, and +314 bp :⑩ of the UCP3 pro-
moter. The primers used for reporter plasmid construc-
tion are listed in Additional file 1: Table S2. The relative
luciferase activity of each reporter was compared with
the positive control using the protocol described above.
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Statistical analysis
The results are shown as the mean ± SD. The significance
of differences was determined by one-way ANOVA and
post hoc Bonferroni/Tukey test for multiple comparisons
using SPSS 17.0 software. A p-value of P < 0.05 was con-
sidered statistically significance.
Results
VD3 supplementation protected against high fat diet-
induced obesity
VD3 limited the body weight gain of HFD mice
High-fat diet feeding mice treated with cholecalciferol
(HFVD) gained less weight compared to the HFD group
(Additional file 2: Figure S1). After the fifth week, the
difference in weight gain between groups was significant
(Fig. 1a, P < 0.05). The weight gain of HFD mice was
206.7 % of that of the NFD group. On the other hand,
the weight gain of HFVD mice was 51.8 % compared to
the NFD group (Fig. 1b, P < 0.01). Food consumption
was not different between each group (Fig. 1c).
VD3 decreased fat mass in HFD mice
We measured the tissue weight of epididymis adipose,
kidney adipose, and mesentery adipose to investigate fat
distribution. The weight of epididymis adipose and mes-
entery adipose was significantly higher in the HFD group
compared to the NFD group by 142.8 and 184.0 %, respect-
ively (P < 0.01). Treatment with cholecalciferol increased
tissue weight by 44.4 and 48.4 %, respectively (P < 0.01)
compared to NFD mice (Fig. 1d).
VD3 had no effects on altering serum lipid
Glucose and serum lipids include TC, LDL-C, HDL-C,
and TG. The serum levels of the HFD and the HFVD
groups had no significant change when compared with
the NFD group (data not shown).
VD3 elevated the mRNA expression of UCP3 in the thigh
rectus femoris muscle
To explore the potential mechanism of the reducing
body weight effects of cholecalciferol, we examined the
mRNA expression of various target genes that were re-
ported to be involved in lipid, glucose and energy metab-
olisms, paying special attention to UCP genes. We
measured UCP3 mRNA levels in the thigh muscle
using qRT-PCR. The expression of UCP3 mRNA in
the thigh muscle increased in the cholecalciferol
treated HFVD group compared with the untreated
HFD group (P < 0.01, Fig. 2a). We also examined that
VDR was present in white adipose tissue, liver, and muscle
by PCR agarose electrophoresis in every group (Additional
file 3: Figure S2). These results suggest cholecalciferol
Fig. 1 VD3 decreased body weight and fat mass of HFD group mice. The individual body weight (a) and the food consumption (c) were
measured daily and weekly, respectively. After 9 weeks, body weight gain was analyzed among each group (b). VD3 altered fat mass of mice fed
a high-fat diet (d). n = 7. Compared to NFD, ##; P < 0.01. Compared with HFD, *; P < 0.05, **; P < 0.01
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decreases body weight and may alter energy metabolism
by involving UCP3 (Fig. 2b). We also observed the
expression level of mRNA of UCP1 in the brown and
white adipose tissues. Those were not elevated by ad-
ministration of VD3 (Additional file 4: Figure S3).
Relative luciferase activities of UCP3-pro-luc were dose
dependent on calcitriol in three muscle cell lines
To determine the effects of calcitriol on relative lucifer-
ase activities of UCP3-pro-luc, we used the Dual Lucifer-
ase Assay in C2C12 cells (Fig. 3a), L6 (Fig. 3b), and
H-EMC-SS (Fig. 3c). Compared with the vehicle con-
trol, luciferase activity was significantly increased in
a dose dependent manner as concentrations of calci-
triol (0.1–100 nM) increased. The UCP3-pro-luc pro-
moter activity in H-EMC-SS cells was enhanced by 1 nM
(P < 0.05), 10 nM (P < 0.01), and 100 nM (P < 0.01) calci-
triol. Similar effects were observed in both L6 and C2C12
cells by 100 nM calcitriol (P < 0.05).
UCP and nuclear receptor genes were affected by
calcitriol especially combined with VDR
To detect the effects of VD3 on energy metabolism, we
analyzed the expression of UCP3 mRNA in C2C12
(Fig. 4a), L6 (Fig. 4b), and H-EMC-SS (Fig. 4c) both
untransfected and transfected with VDR. In untrans-
fected VDR C2C12 cells, UCP3 mRNA increased in the
presence of 50 nM calcitriol (P < 0.05). In VDR trans-
fected cells, the same patterns were amplified (P < 0.01).
The siRNAs against mouse UCP3 diminished expression
of the respective transcript (Fig. 4a).
Identification of a functional consensus sequence of VDR
binding sites in the UCP3 promoter
All truncated reporter constructs had at least some pro-
moter activity although the actual strength was dependent
on the length of UCP3 promoter (Fig. 5a). Above all, abro-
gation between -861 and -476 on the UCP3 promoter
significantly decreased the transcriptional activity to 54.7
± 2.4 % of that -861UCP3-pro-Luc (Fig. 5a). Therefore, the
results indicate that there are multiple functional VDREs
in the UCP3 promoter. We examined luciferase activity of
our generated reporter constructs containing putative
VDREs. The magnitude of activation was dependent on
sequence similarity to the osteopontin VDRE (AGGT-
CAcgaAGGTCA) (Fig. 5b, Additional file 1: Table S2
and S4). These results suggest that the functional
VDREs are located at -2200, -1561, -634, and +314 bp of
the proximal region of the UCP3 promoter.
Discussion
In this study, we determined the effects of VD3 on obes-
ity in mice fed high-fat diets. Body weight, weight gain,
and white adipose tissue decreased in mice treated with
VD3. Some metabolism genes, including UCP3, had al-
tered gene expression in VD3 treated mice, suggesting
variation in mitochondrion function might be involved.
In addition, we identified the functional consensus se-
quence of calcitriol/VDR in the UCP3 promoter.
Some researchers have shown that liganded VDR re-
presses PPARγ expression via inhibition of C/EBPβ ex-
pression and inhibits adipogenesis [31, 32]. Other studies
suggest that the anti-adipogenic effect of calcitriol-
suppressing transcription factor PPARγ is mediated by
WNT10B and nuclear β-catenin expression levels in
3 T3-L1 preadipocytes [33]. To examine if VD3 decreases
obesity, we fed C57BL/6 mice a high-fat diet for 9 weeks
to mimic the pathogenesis of obesity, which results in in-
creased body weight gain and other metabolic distur-
bances by affecting food intake and peripheral metabolism
[34]. Based on the previously described association be-
tween obesity and VD3, we investigated the role of VD3
Fig. 2 VD3 increased UCP3 mRNA expression in muscles. The effects of VD3 on UCP3 mRNA expression in the thigh rectus femoris muscle of
mice fed a high-fat diet. n = 5. Compared with NFD, **; P < 0.01
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Fig. 3 Calcitriol enhanced relative luciferase activity in a dose dependent manner. UCP3-pro-luc was transfected into C2C12 cells (a), L6
cells (b), and H-EMC-SS cells (c). Relative luciferase activity was analyzed by Dual Luciferase Assay after stimulation with calcitriol. n = 3,
compared with vehicle, *: P < 0.05; **: P < 0.01
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Fig. 4 (See legend on next page.)
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on modulating body weight. Body weight significantly in-
creased after 4 weeks for the HFD group while treatment
with VD3 (HFVD) resulted in decreased body weight be-
ginning the fifth week compared to the HFD group
(Fig. 1a). Similar to changes in body weight, VD3 supple-
mented mice gained less weight than HFD mice in spite of
that all mice have the almost same original body weight.
However, daily food consumption was almost constant,
implying appetite was not affected between groups and
that differences in weight gain cannot be attributed to dif-
ferences in calorie intake (Fig. 1c). We measured the mass
of visceral adipose tissue and observed changes in the
weight of epididymis adipose and mesentery adipose in
HFD mice in accordance with changes in body weight
(Fig. 1d). We speculate that decreased adipose tissue
weight in VD3 supplemented mice is due to the inhibition
of adipogenesis.
Levels of blood lipid total-cholesterol, LDL-cholesterol,
HDL-cholesterol, triglyceride, and glucose were compar-
able between treatments, suggesting the variation in body
weight and adipose tissue did not affect serum lipid levels
(data not shown). To investigate the mechanism of VD3-
associated inhibition of weight gain, we measured mRNA
levels by qRT-PCR in muscle and adipose samples. The
results show weight loss by VD3 supplementation may
occur by UCP3 in thigh rectus femoris muscle, suggesting
VD3 may influence energy metabolism and thereby alter
body weight. Recent findings also highlight a new role for
calcitriol and its receptor VDR in adipose tissue energy
homeostasis [35], especially in regulating UCP expression
[28]. We identified the existence of VDR by PCR gel elec-
trophoresis, suggesting that VD3 modulates body weight
by interacting with its receptor VDR.
To explore the role of VD3 in the modulation of body
weight, we performed in vitro experiments using C2C12,
L6, H-EMC-SS cells to observe the expression of genes
involved in energy and lipid metabolism, including
UCP3. These three cell types represent both different
species and different muscle cell types. We employed H-
EMC-SS cells, as substitutes for myocyte or myoblast
cell lines to examine VD3 action on human derived cell
line. We demonstrated that calcitriol upregulates the ex-
pression of UCP3 in all cell types, with even higher ex-
pression in pCMX-VDR transfected cells. Those results
underline that UCP3 gene in muscle cell lines are posi-
tively regulated by VDR-mediated gene transcription.
Furthermore, we verified the presence of VDR in these
cells by examining the expression of VDR (Additional
file 5: Figure S4). Expression levels of VDR mRNA were
varied depending on the cell lines, though the level of
them were less than that of the skeletal muscle. To verify
the effect of calcitriol on relative luciferase activities, we
used the Dual Luciferase Assay in UCP3-pro-luc trans-
fected cells. The relative luciferase activities increased
in response to calcitriol in a dose dependent manner
in all cell lines. These data indicate that treatment of
muscle cells with calcitriol increases the promoter ac-
tivity in the presence of UCP3. Therefore, calcitriol
enhances the expression of UCP3 in muscle cell lines
via binding to VDR.
UCP and respiration uncoupling are implicated in nu-
merous physiological and pathological processes, includ-
ing adaptive thermogenesis [36], regulation of fatty acid
oxidation [37], and body weight regulation [38]. UCP3
protects against lipid-induced mitochondrial damage by
facilitating the export of fatty acids that cannot be oxi-
dized from the mitochondrial matrix [39]. The previous
report revealed that the moderate overexpression of
UCP3 led to an increase in mitochondrial oxygen con-
sumption and reduced oxidative phosphorylation effi-
ciency in skeletal muscle fibers [40]. Overexpression of
UCP3 mRNA in mouse skeletal muscle reduces diet-
induced obesity, suggesting that UCP3 has therapeutic
potential in the treatment of obesity [38]. UCP3 is
thought to regulate mitochondrial fatty acid oxidation.
For example, gastrocnemius muscle mitochondria iso-
lated from UCP3+/+ mice can better oxidize fatty acids
and result in lower fatty acid levels than those of UCP3
+/− and UCP3−/− mice [41]. UCP3 protects against body
weight and fat gain [42] and prevents accumulation of
triglycerides in both adipose tissues and muscles [43]
during high-fat feeding. Higher levels of fat are stored in
mice lacking UCP3 that are fed high-fat diets [17]. In
skeletal muscles, reduced mitochondrial uncoupling im-
pairs mitochondrial fatty acid oxidation, leading to fatty
acid and/or metabolite accumulation and increased oxi-
dative stress, which results in obesity [44, 45].
We showed a significant increase in UCP3 mRNA ex-
pression by VD3 in thigh rectus femoris muscles. Add-
itionally, UCP3 mRNA expression increased in both
untransfected and pCMX-VDR-transfected C2C12, L6,
and H-EMC-SS cells. The relative luciferase activity in-
creased in a calcitriol-dose-dependent manner in three
different muscle cells transfected with the UCP3-pro-luc
(See figure on previous page.)
Fig. 4 Calcitriol increased UCP3 mRNA expression in muscle cells. Relative mRNA expression was detected in C2C12 cells (a), L6 cells (b), and H-EMC-
SS cells (c) using qRT-PCR. To investigate the role of calcitriol and VDR on UCP3 mRNA expression, we transfected with a control plasmid ((-) mock) or
VDR expression plasmid ((+) pCMX-VDR). We also performed loss-of-function experiments using selective siRNA against UCP3 (a). Compared with non-
transfected controls, siRNAs against UCP3 strongly reduced the expression of the UCP3. n = 3. Compared with vehicle, *; P < 0.05, **; P < 0.01.
***; P < 0.005
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vector. Therefore, we speculate that UCP3 facilitates mito-
chondrial fatty acid oxidation and decreases oxidative
stress, thus slowing the progression of obesity.
Finally, we analyzed the UCP3 promoter and VDR for
binding site consensus sequences. Deletion analysis of
the UCP3 promoter constructs indicated that the VDREs
Fig. 5 VD3 responsiveness of candidate VDRE upon transient transfection. The schematic structure of the proximal region of the human UCP3
promoter is shown; nucleotides are numbered relative to the transcriptional start site (TSS). The number below the top line denotes the position of the
putative VDRE in the UCP3 promoter as follows; -2200;①, -2043;②, -1867;③, -1561;④, -634;⑤, -595;⑥, -80;⑦, -1;⑧, +162;⑨, and +314;⑩. Each
truncated UCP3-pro-luc reporter construct and CMX-hVDR were co-transfected into HEK-293 cells and relative luciferase activity was compared. a Error
bars represent SD from at least three experiments. n = 3. Compared with the control, *; P < 0.05, ***; P < 0.005. Solid boxes represent putative VDRE with
high sequence similarity to the positive control (more than 80 %). Shadow boxes represent those with medium similarity (more than 70 %), open
boxes represent those with relatively low similarity (more than 60 %) to the positive control. b As a positive control for VD3 responsiveness, we used
the mouse osteopotin VDRE (AGGTCAcgaAGGTCA). Relative luciferase activity of each putative VDRE-luc-reporter construct compared to the positive
control. Each value is expressed as mean ± SD from at least three experiments. Both designated nucleotide number relative to the TSS and sequential
number is shown of the putative VDREs examined. *; P < 0.05 compared to the positive control
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are located at -2200, -1561, -634, and +314 bp. Particu-
larly, without the No. 5 VDRE sited at -634, the UCP3
promoter activity of transcription decreased dramatically
-45.3 ± 2.4 % in comparison to its control. So we de-
duced that the transcriptional activities of calcitriol/VDR
primarily depend on its sequence similarity to that of
osteopontin, which are known to the most potent VDRE
to date. Our results indicate that at least four VDRE-
binding site consensus sequences on the UCP3 promoter
control the transcriptional regulation of UCP3 synergis-
tically depending on the calcitriol/VDR and/or RXR con-
ditions. The liganded VDR binds VDRE on the promoter
of target genes and regulates their expression via the for-
mation of heterodimeric complexes with RXR. The VDR
also can interact with nuclear receptor, such as PPARs,
thyroid hormone receptors, corepressors, coactivators,
and many transcriptional factors [30, 46]. On the con-
trary, UCP3 gene promoter harbors several cis-elements
essential for expression [47–49]. The relative contribu-
tion of those in the regulatory regions to UCP3 gene
expression remains to be clarified.
UCPs are a highly useful molecular target for the treat-
ment of obese patients for whom dietary restriction and
exercise are difficult. However, because the signal trans-
ducers that function downstream of calcitriol/VDR also
participate in high calcemia and urinary stones, investi-
gations into the clinical applications of VD3 and/or cal-
citriol should be conducted cautiously. Therefore, drugs
that selectively regulate VDR, which is expressed in
myocytes, and intentionally regulate only UCP3 may be
used as seeds for further drug development. Such drugs
may be beneficial for supplementing weight reduction
drugs and for obese patients.
Conclusions
In summary, the present study demonstrates that the
regulation energy metabolism, which was hypothesized
to be directly acted on by 1,25(OH)2VD3, involves UCP3
via VDR. Furthermore, UCP3 and VDR is expressed
widely throughout the skeletal muscle in the whole body.
This suggests that circulating 1,25(OH)2VD3 are related
to the direct effects of local thermogenesis and energy
metabolism.
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